Drugs / ATGC-110
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05623410 | Oct 2022 → Feb 2023 | — | ATGC Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATGC-110 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05623410 ↗ |
| Modality | Protein / enzyme biologic | “Botulinum toxin type A(ATGC-110)” NCT05623410 ↗ |
| Route | Intramuscular | “ATGC-110 is a prescription medicine that is injected into muscles and used to improve the moderate to severe glabellar lines.” NCT05623410 ↗ |